Canaccord analyst Susan Anderson initiated coverage of Niagen Bioscience (NAGE) with a Buy rating and $13 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Biosciences Reports Strong Q1 2025 Growth
- Niagen Bioscience’s Clinical Expansion and Strong Financial Performance Drive Buy Rating
- Niagen Bioscience Reports Strong Q1 2025 Growth
- Closing Bell Movers: Arm sinks over 10% as guidance falls short
- Niagen Bioscience Reports Strong Q1 2025 Financial Results